Biocon Boosts Biologics Stake to 98%, Raises ₹4,150 Cr Via QIP

HEALTHCAREBIOTECH

Overview

Biocon Ltd has finalized the acquisition of remaining equity shares in its subsidiary Biocon Biologics Ltd (BBL) from Mylan Inc. for $200 million, elevating its ownership to approximately 98%. This strategic consolidation was supported by a successful ₹4,150 crore Qualified Institutional Placement (QIP). Funds from the QIP will directly finance the Mylan payout, bolstering Biocon's capital structure. Mutual funds were key participants in the placement.

Strategic Consolidation of Biologics Arm

Biocon Ltd has successfully concluded the purchase of the remaining equity shares in its subsidiary, Biocon Biologics Ltd (BBL), from Mylan Inc. for a cash consideration of $200 million. This transaction is the final step in a previously announced deal to acquire a significant portion of BBL's shares, bringing Biocon's fully diluted ownership to approximately 98%. The move aims to fully integrate the biologics division, enhancing operational synergies and strategic flexibility in a competitive global market.

Capital Infusion Via QIP

To fund this substantial acquisition and strengthen its balance sheet, Biocon executed a Qualified Institutional Placement (QIP). The company successfully raised ₹4,150 crore through this issue, with the QIP price fixed at ₹368.35 per share. Notably, major institutional investors, including funds managed by SBI, ICICI, and Mirae Mutual Fund, were significant participants, underscoring strong confidence in Biocon's growth prospects. The proceeds are earmarked for the cash payment to Mylan.

Equity Structure Adjustment

The QIP resulted in an increase in Biocon's total paid-up equity share capital. Following the share issuance, the capital now stands at ₹810.45 crore, comprising 162.09 crore shares, up from the previous figure of ₹754.12 crore representing 150.82 crore shares. This capital adjustment allows for continued investment in research and development while managing acquisition costs. Shares of Biocon Ltd closed at ₹365.00 on the BSE on January 21, 2026, reflecting a minor dip.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.